Ignaty Leshchiner

Ignaty Leshchiner

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Ignaty Leshchiner

Broad Institute of MIT and Harvard, Cambridge, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Cell
Verified
Journal Article
Closed access
AAAdam Abeshouse
Adam Abeshouse
JAJaeil Ahn
Jaeil Ahn
RARehan Akbani
Rehan Akbani
AAAdrian Ally
Adrian Ally
SASamirkumar Amin
Samirkumar Amin
EZErik Zmuda
Erik Zmuda

30 April 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BCBjoern Chapuy
Bjoern Chapuy
CSChip Stewart
Chip Stewart
ADAndrew J. Dunford
Andrew J. Dunford
JKJaegil Kim
Jaegil Kim
AKAtanas Kamburov
Atanas Kamburov
MSMargaret A. Shipp
Margaret A. Shipp

1 October 2016 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JGJustin F. Gainor
Justin F. Gainor
LDLeila Dardaei
Leila Dardaei
SYSatoshi Yoda
Satoshi Yoda
LFLuc Friboulet
Luc Friboulet
ILIgnaty Leshchiner
Ignaty Leshchiner
ASAlice T. Shaw
Alice T. Shaw
Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib and alectinib) upon progression. Second-generation inhibitors are generally effective even in the absence of crizotinib-resistant ALK mutations, likely reflecting incomplete inhibition of ALK by crizotinib in many cases. Herein, we analyzed 103 repeat biopsies from ALK-positive patients progressing on various ALK inhibitors. We find that each ALK inhibitor is associated with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation, ALKG1202R, increases significantly after treatment with second-generation agents. To investigate strategies to overcome resistance to second-generation ALK inhibitors, we examine the activity of the third-generation ALK inhibitor lorlatinib in a series of ceritinib-resistant, patient-derived cell lines, and observe that the presence of ALK resistance mutations is highly predictive for sensitivity to lorlatinib, whereas those cell lines without ALK mutations are resistant. Significance: Secondary ALK mutations are a common resistance mechanism to second-generation ALK inhibitors and predict for sensitivity to the third-generation ALK inhibitor lorlatinib. These findings highlight the importance of repeat biopsies and genotyping following disease progression on targeted therapies, particularly second-generation ALK inhibitors. Cancer Discov; 6(10); 1118–33. ©2016 AACR. See related commentary by Qiao and Lovly, p. 1084. This article is highlighted in the In This Issue feature, p. 1069

6 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
VAViktor A. Adalsteinsson
Viktor A. Adalsteinsson
GHGavin Ha
Gavin Ha
SFSamuel S. Freeman
Samuel S. Freeman
ACAtish Choudhury
Atish Choudhury
DSDaniel G. Stover
Daniel G. Stover
MMMatthew Meyerson
Matthew Meyerson
Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is uncertain. Here we report ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations. We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing. Using whole-exome sequencing, we validate the concordance of clonal somatic mutations (88%), copy number alterations (80%), mutational signatures, and neoantigens between cfDNA and matched tumor biopsies from 41 patients with ≥10% cfDNA tumor content. In summary, we provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing.

5 February 2020 in Nature
Verified
Journal Article
Open access
PDF file
MGMoritz Gerstung
Moritz Gerstung
CJClemency Jolly
Clemency Jolly
ILIgnaty Leshchiner
Ignaty Leshchiner
SDStefan C. Dentro
Stefan C. Dentro
SGSantiago Gonzalez
Santiago Gonzalez
PLPeter Van Loo
Peter Van Loo
Cancer develops through a process of somatic evolution1,2. Sequencing data from a single biopsy represent a snapshot of this process that can reveal the timing of specific genomic aberrations and the changing influence of mutational processes3. Here, by whole-genome sequencing analysis of 2,658 cancers as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA)4, we reconstruct the life history and evolution of mutational processes and driver mutation sequences of 38 types of cancer. Early oncogenesis is characterized by mutations in a constrained set of driver genes, and specific copy number gains, such as trisomy 7 in glioblastoma and isochromosome 17q in medulloblastoma. The mutational spectrum changes significantly throughout tumour evolution in 40% of samples. A nearly fourfold diversification of driver genes and increased genomic instability are features of later stages. Copy number alterations often occur in mitotic crises, and lead to simultaneous gains of chromosomal segments. Timing analyses suggest that driver mutations often precede diagnosis by many years, if not decades. Together, these results determine the evolutionary trajectories of cancer, and highlight opportunities for early cancer detection.

1 February 2017 in Cancer Cell
Verified
Journal Article
Closed access
LFLauren Fishbein
Lauren Fishbein
ILIgnaty Leshchiner
Ignaty Leshchiner
VWVonn Walter
Vonn Walter
LDLudmila Danilova
Ludmila Danilova
ARA. Gordon Robertson
A. Gordon Robertson
EZErik Zmuda
Erik Zmuda